Document is current
Any future updates will be listed below
-
Authors
Hakim, Seifeldin https://orcid.org/0000-0001-7898-9611
Aneese, Andrew M. https://orcid.org/0000-0002-2927-6102
Edhi, Ahmed https://orcid.org/0000-0002-9193-1462
Shams, Christienne https://orcid.org/0000-0003-3707-2457
Purohit, Treta
Cannon, Michael E.
Cappell, Mitchell S. https://orcid.org/0000-0003-3445-5428
- License Information
-
More Information
Article History
Received: 16 June 2019
Accepted: 9 January 2020
First Online: 23 January 2020
Compliance with Ethical Standards
:
: None for all authors. None of the authors received any financial support for writing this article. In particular, Dr. Cappell, as a consultant of the United States Food and Drug Administration (FDA) Advisory Committee for Gastrointestinal Drugs, affirms that this paper does not discuss any proprietary, confidential, pharmaceutical data submitted to the FDA. Dr. Cappell was also a member of the speaker’s bureau for AstraZeneca and Daiichi Sankyo, co-marketers of Movantik until more than 1 year ago. Dr. Cappell received a one-time honorarium from Shire and Mallinckrodt more than 1 year ago. This work does not discuss any drug manufactured or marketed by AstraZeneca, Daiichi Sankyo, Shire, or Mallinckrodt.
